Psoriatic Arthritis Treatment Market Size & Growth Forecast 2027–2036, By Segments (Route of Administration, Drug Type, Age Group, Medication Type, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Psoriatic Arthritis Treatment Market size was valued at USD 12.94 Billion in 2026 and is anticipated to grow at 10.28% CAGR from 2027 to 2036, surpassing USD 34.43 Billion by 2036. The industry revenue for 2027 is calculated at USD 14.07 Billion.

• Base Year Value (2026): USD 12.94 Billion
• CAGR (2027-2036): 10.28%
• Forecast Year Value (2036): USD 34.43 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Psoriatic Arthritis Treatment Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America led in 2025, supported by advanced healthcare infrastructure, specialized rheumatology access, greater disease awareness, and availability of advanced therapeutic approaches.
  • Asia Pacific is growing fastest as healthcare access, specialist diagnosis, healthcare investment, and availability of advanced treatments improve across the region.

• Segment Momentum:

  • Injectable therapies held a 61.16% market share in 2025 because biologic treatments provide targeted disease control for moderate to severe patients, delivering sustained symptom relief and slowing disease progression.
  • DMARDs are the fastest-growing drug type due to their broad role in slowing disease progression, preserving joint function, supporting early intervention strategies, and expanding access to long-term treatment options.

• Market Expansion Drivers:

  • Rising prevalence and improved diagnosis of psoriatic arthritis driving treatment demand
  • Expanding R&D investments accelerating biologics and targeted therapy development
  • Advancements in diagnostic imaging enabling earlier and more accurate disease detection

• Leading Market Participants:

  Leading companies in the psoriatic arthritis treatment market include AbbVie Inc. (United States), Amgen Inc. (United States), Bristol-Myers Squibb Company (United States), Johnson & Johnson (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), UCB S.A. (Belgium), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 12.94 Billion
  • 2027 Estimated Market Size: USD 14.07 Billion
  • Projected Market Size: USD 34.43 Billion by 2036
  • Growth Forecasts: 10.28% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Injectable (Route of Administration) | Biological Agents (Drug Type) | 41-60 (Age Group) | Branded (Medication Type) | Hospital Pharmacies (Distribution Channel)
  • Emerging Opportunity Segment: Oral (Route of Administration) | Disease-modifying Antirheumatic Drugs (DMARDs) (Drug Type) | 61 Above (Age Group) | Generics (Medication Type) | Online Pharmacies (Distribution Channel)

Market Growth Drivers and Industry Trends

Rising prevalence and improved diagnosis of psoriatic arthritis driving treatment demand

Increasing recognition of psoriatic arthritis symptoms and improvements in clinical diagnosis are expanding the patient base requiring targeted therapies, which will drive the psoriatic arthritis treatment market growth. Healthcare providers are becoming more capable of identifying the condition at earlier stages, enabling timely intervention and reducing long-term joint damage. Greater awareness among patients and physicians is improving diagnosis rates, leading to increased demand for pharmacological treatments that address inflammation and disease progression. The growing focus on early disease management is encouraging broader utilization of advanced therapeutic options.

Expanding R&D investments accelerating biologics and targeted therapy development

Growing investment in pharmaceutical research is advancing the development of innovative biologics and precision-based treatments, which will boost the psoriatic arthritis treatment market expansion. Drug developers are focusing on therapies that target specific inflammatory pathways to improve treatment effectiveness and provide alternatives for patients with varying disease severity. Continued innovation is expanding the range of available treatment approaches while supporting improvements in patient outcomes. The increasing focus on personalized medicine is encouraging further development of next-generation therapies for chronic inflammatory conditions.

Advancements in diagnostic imaging enabling earlier and more accurate disease detection

Improved imaging technologies are enhancing the ability of clinicians to detect joint inflammation and structural changes associated with psoriatic arthritis, which will propel the psoriatic arthritis treatment market growth. Advanced diagnostic approaches allow healthcare professionals to evaluate disease progression more accurately and make informed treatment decisions at earlier stages. Better visualization of affected areas is supporting more personalized treatment planning and improving monitoring of therapeutic response. These diagnostic improvements are strengthening clinical management practices and increasing the adoption of appropriate treatment strategies.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence and improved diagnosis of psoriatic arthritis driving treatment demand	2%	High	North America, Europe	High	Near Term
Expanding R&D investments accelerating biologics and targeted therapy development	1.9%	High	North America, Asia Pacific	High	Mid Term
Advancements in diagnostic imaging enabling earlier and more accurate disease detection	1.7%	High	Europe, North America	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

The psoriatic arthritis treatment market was led by North America in 2026, reflecting the region's advanced healthcare infrastructure, strong access to specialized rheumatology services, and growing emphasis on early diagnosis and disease management. Increasing awareness of psoriatic arthritis and the availability of advanced therapeutic approaches are supporting treatment adoption. Well-established healthcare systems and continued development of targeted treatment options are also helping strengthen the region's market position.

Asia Pacific is projected to register the fastest growth in the psoriatic arthritis treatment market, driven by improving healthcare access, rising awareness of inflammatory and autoimmune disorders, and expanding availability of specialized treatments. Greater investment in healthcare infrastructure is enabling more patients to access specialist diagnosis and long-term disease management. Increasing patient awareness and the gradual expansion of advanced treatment options are expected to further support market development across the region.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Route of Administration Segment Analysis: Injectable (Largest Segment) vs Oral (Fastest-Growing Segment)

The injectable route of administration segment led the psoriatic arthritis treatment market with a market share of 61.16% in 2026, primarily due to the widespread use of biologic therapies for managing moderate to severe disease. Injectable formulations enable targeted therapeutic action and are commonly prescribed for patients who require sustained disease control and symptom relief when conventional treatments are insufficient. Their established clinical effectiveness in reducing joint inflammation and slowing disease progression has reinforced their leading position, while ongoing advancements in biologic drug development continue to support long-term adoption.

The oral route of administration segment is expected to witness the fastest growth as healthcare providers and patients increasingly seek convenient treatment options that simplify long-term disease management. Oral therapies improve treatment accessibility by eliminating the need for injections and can enhance patient adherence, particularly among individuals requiring continuous medication. Expanding availability of advanced oral therapies and growing emphasis on patient-centered care are contributing to the rapid development of this segment.

Drug Type Segment Analysis: Biological Agents (Largest Segment) vs Disease-modifying Antirheumatic Drugs (DMARDs) (Fastest-Growing Segment)

Biological agents accounted for the largest share of 38.12% in 2026, reflecting their significant role in treating patients with active psoriatic arthritis who require targeted immune modulation. These therapies are widely utilized because they address specific inflammatory pathways associated with disease progression, helping improve joint function while reducing long-term structural damage. Continued innovation in biologic treatments and increasing clinical preference for precision-based therapies have strengthened the segment's market leadership.

In the psoriatic arthritis treatment market, the disease-modifying antirheumatic drugs (DMARDs) segment is anticipated to be the fastest-growing owing to their broad use in slowing disease progression and preserving joint function during long-term treatment. DMARDs remain an important component of therapeutic strategies because they can be administered at earlier stages of disease management and are often incorporated into comprehensive treatment plans. Growing awareness of early intervention and expanding access to disease-modifying therapies continue to support the segment's rapid growth.

Age Group Segment Analysis: 41-60 (Largest Segment) vs 61 Above (Fastest-Growing Segment)

The 41–60 age group segment held the largest share of 50.99% in 2026, supported by the high prevalence of psoriatic arthritis diagnosis within this economically active population. Individuals in this age group frequently seek treatment to maintain mobility, productivity, and quality of life, contributing to sustained demand for effective therapeutic options. Increased awareness of early diagnosis and greater access to specialized rheumatology care have further reinforced the segment's dominant position.

The 61 above age group segment is projected to experience the fastest growth as aging populations contribute to a rising number of patients requiring long-term management of inflammatory joint disorders. Older adults often require comprehensive treatment approaches to address disease progression while preserving functional independence. Improvements in healthcare accessibility and the availability of diverse therapeutic options are expected to encourage increased treatment adoption within this age category.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Route of Administration	Topical, Oral, Injectable	Injectable	Oral
Drug Type	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-modifying Antirheumatic Drugs (DMARDs), Biological Agents, Others	Biological Agents	Disease-modifying Antirheumatic Drugs (DMARDs)
Age Group	Below 18 Years, 19-40, 41-60, 61 Above	41-60	61 Above
Medication Type	Branded, Generics	Branded	Generics
Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies	Hospital Pharmacies	Online Pharmacies

Competitive Landscape and Market Positioning

Major players in the psoriatic arthritis treatment market:

1. AbbVie, Inc. (United States)
2. Amgen, Inc. (United States)
3. Bristol-Myers Squibb Company (United States)
4. Johnson & Johnson (United States)
5. Pfizer, Inc. (United States)
6. Novartis AG (Switzerland)
7. Eli Lilly and Company (United States)
8. UCB S.A. (Belgium)
9. Sanofi (France)
10. Sun Pharmaceutical Industries Ltd. (India)

The competitive environment is shifting toward differentiated treatment approaches as market participants focus on improving therapeutic outcomes, patient adherence, and disease management experiences. Established pharmaceutical developers continue refining targeted therapies and expanding clinical capabilities, while emerging players explore more personalized approaches that address variations in disease progression and patient response. Innovation in biologic therapies, oral treatments, and supportive care strategies is intensifying rivalry as companies seek stronger positioning within evolving treatment pathways. Competitive momentum is also being shaped by efforts to integrate digital monitoring tools and patient-centric services, creating a broader contest around long-term disease management rather than treatment delivery alone.

Industry Development/News

Company Name	Date	Key Development
Johnson & Johnson	May-26	Johnson & Johnson secured FDA label expansion for Tremfya (guselkumab) to include data showing the inhibition of structural joint damage progression in adults with active psoriatic arthritis. The authorization, backed by Phase 3b APEX trial results, strengthens the drug's competitive positioning in the biologic segment.
Sun Pharmaceutical Industries	Mar-26	Sun Pharmaceutical Industries announced that the FDA accepted its supplemental application to expand the label indication for Ilumya to include active psoriatic arthritis. The submission, supported by positive Phase 3 clinical data, represents a key regulatory step toward diversifying the therapy's commercial portfolio.
Alvotech	Apr-24	Alvotech and Teva Pharmaceuticals received FDA approval for their biosimilar, Selarsdi, as a lower-cost alternative to Stelara for treating moderate-to-severe plaque psoriasis and active psoriatic arthritis. The regulatory milestone introduces new biosimilar competition and alters market pricing dynamics.
Novartis	Oct-23	Novartis received U.S. FDA approval for an intravenous formulation of Cosentyx to treat adults with active psoriatic arthritis and axial spondyloarthritis. The approval commercializes a new healthcare administration route, expanding patient access alongside existing biologic options.